Publication | Open Access

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

AllergyAutoimmune DiseaseNon-randomised Phase 1B/2aImmunologyAutoimmunityImmunotherapyMedicineClinical ActivityMyasthenia Gravis